Evaluation of renal function in patients with type 1 diabetes mellitus implementing reproductive function in assisted reproductive technology protocols

Abstract

The prevalence of type 1 diabetes mellitus has increased significantly among women of reproductive age over the past two decades. Despite improved glycemic control and intensified insulin therapy, patients with diabetes still suffer from many reproductive problems, which often makes this group of patients potential participants in assisted reproductive technology programs under certain conditions. Diabetic nephropathy is one of the most serious complications of type 1 diabetes mellitus. It ranks first in the structure of chronic kidney disease and is a common cause of end-stage renal failure, disability, and mortality. Early diagnosis and identification of specific markers of diabetic nephropathy will allow for timely initiation of nephroprotective therapy to slow the progression of diabetic kidney damage.

This review article is based on the results of the PubMed, Frontiers, and ResearchGate search queries from 2016 to 2023. We analyzed worldwide and domestic data on the impact of type 1 diabetes mellitus on kidney function, the influence of sex hormones on diabetic nephropathy, and the importance of the personalized approach to this group of patients at the pre-pregnancy stage, especially those planning treatment within assisted reproductive technology programs.

Keywords

type 1 diabetes mellitus / diabetic nephropathy / preconception care / diabetic nephropathy biomarkers / assisted reproductive technology

References

[1] Dedov II, Shestakova MV, Mayorov AYu, editors. Standards of specialized diabetes care. 11th edn. Moscow; 2023. (In Russ.) doi: 10.14341/DM13042

[2] Алгоритмы специализированной медицинской помощи больным сахарным диабетом / под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й вып. Москва, 2023. doi: 10.14341/DM13042

[3] IDF Diabetes. Atlas. 10th edn. Brussels: International Diabetes Federation; 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK581934/

[4] IDF Diabetes. Atlas. 10th edn. Brussels: International Diabetes Federation, 2021. Режим доступа: https://www.ncbi.nlm.nih.gov/books/NBK581934/. Дата обращения: 13.12.2023.

[5] Federal register of patients with diabetes mellitus. (In Russ.) Available from: https://sd.diaregistry.ru/content/epidemiologiya.html

[6] Федеральный регистр больных с сахарным диабетом. Режим доступа: https://sd.diaregistry.ru/content/epidemiologiya.html. Дата обращения: 13.12.2023.

[7] Shestakova MV. Diabetes mellitus and chronic kidney disease: Possibilities of prediction, early diagnosis, and nephroprotection in the 21st century. Terapevticheskii arkhiv. 2016;88(6):84–88. EDN: WAIPBX doi: 10.17116/terarkh201688684-88

[8] Шестакова М.В. Сахарный диабет и хроническая болезнь почек: возможности прогнозирования, ранней диагностики и нефропротекции в XXI веке // Терапевтический архив. 2016. Т. 88, № 6. C. 84–88. EDN: WAIPBX doi: 10.17116/terarkh201688684-88

[9] Xie Y, Bowe B, Mokdad AH, et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int. 2018;94(3):567–581. doi: 10.1016/j.kint.2018.04.011

[10] Xie Y., Bowe B., Mokdad A.H., et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016 // Kidney Int. 2018. Vol. 94, N. 3. P. 567–581. doi: 10.1016/j.kint.2018.04.011

[11] Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392(10159):2052–2090. doi: 10.1016/S0140-6736(18)31694-5

[12] Foreman K.J., Marquez N., Dolgert A., et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories // Lancet. 2018. Vol. 392. N. 10159. P. 2052–2090. doi: 10.1016/S0140-6736(18)31694-5

[13] Shamkhalova MS, Vikulova OK, Zheleznyakova AV, et al. Trends in the epidemiology of chronic kidney disease in Russian Federation according to the Federal Diabetes Register (2013–2016). Diabetes mellitus. 2018;21(3):160–169. EDN: XYEBFB doi: 10.14341/DM9687

[14] Шамхалова М.Ш., Викулова О.К., Железнякова А.В., и др. Эпидемиология хронической болезни почек в Российской Федерации по данным Федерального регистра взрослых пациентов с сахарным диабетом (2013–2016) // Сахарный диабет. 2018. Т. 21, № 3. С. 160–169. EDN: XYEBFB doi: 10.14341/DM9687

[15] Hovind P, Tarnow L, Rossing P, et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ. 2004;328(7448):1105. doi: 10.1136/bmj.38070.450891.FE

[16] Hovind P., Tarnow L., Rossing P., et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study // BMJ. 2004. Vol. 328, N. 7448. P. 1105. doi: 10.1136/bmj.38070.450891.FE

[17] Herman-Edelstein M, Doi SQ. Pathophysiology of diabetic nephropathy. In: Blaine J. editors. Proteinuria: basic mechanisms, pathophysiology and clinical relevance. Cham(Switzerland): Springer; 2016. P. 41–65.

[18] Herman-Edelstein M., Doi S.Q. Pathophysiology of diabetic nephropathy. In: Blaine J., editor. Proteinuria: basic mechanisms, pathophysiology and clinical relevance. Cham(Switzerland): Springer, 2016. P. 41–65.

[19] Li JH, Wang W, Huang XR, et al. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am J Pathol. 2004;164(4):1389–1397. doi: 10.1016/S0002-9440(10)63225-7

[20] Li J.H., Wang W., Huang X.R., et al. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway // Am J Pathol. 2004. Vol. 164, N. 4. P. 1389–1397. doi: 10.1016/S0002-9440(10)63225-7

[21] Tan AL, Forbes JM, Cooper ME. AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol. 2007;27(2):130–143. doi: 10.1016/j.semnephrol.2007.01.006

[22] Tan A.L., Forbes J.M., Cooper M.E. AGE, RAGE, and ROS in diabetic nephropathy // Semin Nephrol. 2007. Vol. 27, N. 2. P. 130–143. doi: 10.1016/j.semnephrol.2007.01.006

[23] Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011;7(6):327–340. doi: 10.1038/nrneph.2011.51

[24] Navarro-González J.F., Mora-Fernández C., Muros de Fuentes M., et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy // Nat Rev Nephrol. 2011. Vol. 7, N. 6. P. 327–340. doi: 10.1038/nrneph.2011.51

[25] Xu Y, Nie L, Yin YG, et al. Resveratrol protects against hyperglycemia-induced oxidative damage to mitochondria by activating SIRT1 in rat mesangial cells. Toxicol Appl Pharmacol. 2012;259(3):395–401. doi: 10.1016/j.taap.2011.09.028

[26] Xu Y., Nie L., Yin Y.G., et al. Resveratrol protects against hyperglycemia-induced oxidative damage to mitochondria by activating SIRT1 in rat mesangial cells // Toxicol Appl Pharmacol. 2012. Vol. 259, N. 3. P. 395–401. doi: 10.1016/j.taap.2011.09.028

[27] Ruiz-Ortega M, Rayego-Mateos S, Lamas S, et al. Targeting the progression of chronic kidney disease. Nat Rev Nephrol. 2020;16(5):269–288. doi: 10.1038/s41581-019-0248-y

[28] Ruiz-Ortega M., Rayego-Mateos S., Lamas S., et al. Targeting the progression of chronic kidney disease // Nat Rev Nephrol. 2020. Vol. 16, N. 5. P. 269–288. doi: 10.1038/s41581-019-0248-y

[29] Smith MJ, Simmons KM, Cambier JC. B cells in type 1 diabetes mellitus and diabetic kidney disease. Nat Rev Nephrol. 2017;13(11):712–720. doi: 10.1038/nrneph.2017.138

[30] Smith M.J., Simmons K.M., Cambier J.C. B cells in type 1 diabetes mellitus and diabetic kidney disease // Nat Rev Nephrol. 2017. Vol. 13, N. 11. P. 712–720. doi: 10.1038/nrneph.2017.138

[31] A/L B Vasanth Rao VR, Tan SH, Candasamy M, et al. Diabetic nephropathy: an update on pathogenesis and drug development. Diabetes Metab Syndr. 2019;13(1):754–762. doi: 10.1016/j.dsx.2018.11.054

[32] A/L B Vasanth Rao V.R., Tan S.H., Candasamy M., et al. Diabetic nephropathy: an update on pathogenesis and drug development // Diabetes Metab Syndr. 2019. Vol. 13, N. 1. P. 754–762. doi: 10.1016/j.dsx.2018.11.054

[33] Liu Y, Su YY, Yang Q, et al. Stem cells in the treatment of renal fibrosis: a review of preclinical and clinical studies of renal fibrosis pathogenesis. Stem Cell Res Ther. 2021;12(1):333. doi: 10.1186/s13287-021-02391-w

[34] Liu Y., Su Y.Y., Yang Q., et al. Stem cells in the treatment of renal fibrosis: a review of preclinical and clinical studies of renal fibrosis pathogenesis // Stem Cell Res Ther. 2021. Vol. 12, N. 1. P. 333. doi: 10.1186/s13287-021-02391-w

[35] Sugahara M, Pak WLW, Tanaka T, et al. Update on diagnosis, pathophysiology, and management of diabetic kidney disease. Nephrology. 2021;26(6):491–500. doi: 10.1111/nep.13860

[36] Sugahara M., Pak W.L.W., Tanaka T., et al. Update on diagnosis, pathophysiology, and management of diabetic kidney disease // Nephrology. 2021. Vol. 26, N. 6. P. 491–500. doi: 10.1111/nep.13860

[37] Tuttle KR. Back to the future: glomerular hyperfiltration and the diabetic kidney. Diabetes. 2017;66(1):14–16. doi: 10.2337/dbi16-0056

[38] Tuttle K.R. Back to the future: glomerular hyperfiltration and the diabetic kidney // Diabetes. 2017. Vol. 66, N. 1. P. 14–16. doi: 10.2337/dbi16-0056

[39] Rabbani N, Thornalley PJ. Advanced glycation end products in the pathogenesis of chronic kidney disease. Kidney Int. 2018;93(4):803–813. doi: 10.1016/j.kint.2017.11.034

[40] Rabbani N., Thornalley P.J. Advanced glycation end products in the pathogenesis of chronic kidney disease // Kidney Int. 2018. Vol. 93, N. 4. P. 803–813. doi: 10.1016/j.kint.2017.11.034

[41] Opazo-Ríos L, Mas S, Marín-Royo G, et al. Lipotoxicity and diabetic nephropathy: novel mechanistic insights and therapeutic opportunities. Int J Mol Sci. 2020;21(7). doi: 10.3390/ijms21072632

[42] Opazo-Ríos L., Mas S., Marín-Royo G., et al. Lipotoxicity and diabetic nephropathy: novel mechanistic insights and therapeutic opportunities // Int J Mol Sci. 2020. Vol. 21, N .7. P. 2632. doi: 10.3390/ijms21072632

[43] Russian Association of Endocrinologists. Type 1 diabetes mellitus in adults. Clinical recommendations. 2022. (In Russ.) Available from: https://cr.minzdrav.gov.ru/schema/286_2

[44] Российская ассоциация эндокринологов. Сахарный диабет 1 типа у взрослых. Клинические рекомендации. 2022. Режим доступа: https://cr.minzdrav.gov.ru/schema/286_2. Дата обращения: 13.12.2023

[45] Zuraeva ZT. Predicting the risk of diabetic nephropathy in patients with type 1 diabetes mellitus and assessing the nephroprotective effects of incretin therapy [dissertation]. Moscow; 2019. Available from: https://www.dissercat.com/content/prognozirovanie-riska-diabeticheskoi-nefropatii-u-bolnykh-sakharnym-diabetom-1-tipa-i-otsenk (In Russ.) EDN: NNPMAZ

[46] Зураева З.Т. Прогнозирование риска диабетической нефропатии у больных с сахарным диабетом 1 типа и оценка нефропротективных эффектов терапии инкретинами: автореф. дис. … канд. мед. наук. Москва, 2019. Режим доступа: https://www.dissercat.com/content/prognozirovanie-riska-diabeticheskoi-nefropatii-u-bolnykh-sakharnym-diabetom-1-tipa-i-otsenk. Дата обращения: 13.12.2023. EDN: NNPMAZ

[47] Khan NU, Lin J, Liu X, et al. Insights into predicting diabetic nephropathy using urinary biomarkers. Biochim Biophys Acta Proteins Proteom. 2020;1868(10). doi: 10.1016/j.bbapap.2020.140475

[48] Khan N.U., Lin J., Liu X., et al. Insights into predicting diabetic nephropathy using urinary biomarkers // Biochim Biophys Acta Proteins Proteom. 2020. Vol. 1868, N. 10. doi: 10.1016/j.bbapap.2020.140475

[49] Satirapoj B. Tubulointerstitial Biomarkers for diabetic nephropathy. J Diabetes Res. 2018;2018. doi: 10.1155/2018/2852398

[50] Satirapoj B. Tubulointerstitial biomarkers for diabetic nephropathy // J Diabetes Res. 2018. Vol. 2018. doi: 10.1155/2018/2852398

[51] Borovik NB, Yarmolinskaya MI, Gkavnova OB, et al. Prospects of using cystatin C as an early predictor of diabetic nephropathy. Journal of Obstetrics and Women’s Diseases. 2019;68(3):15–24. EDN: VKTXBM doi: 10.17816/JOWD68315-24

[52] Боровик Н.В., Ярмолинская М.И., Главнова О.Б., и др. Новые возможности использования цистатина С как предиктора ранней диагностики диабетической нефропатии // Журнал акушерства и женских болезней. 2019. Т. 68, № 3. С. 15–24. EDN: VKTXBM doi: 10.17816/JOWD68315-24

[53] Stevens LA, Schmid CH, Greene T, et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 2009;75(6):652–660. doi: 10.1038/ki.2008.638

[54] Stevens L.A., Schmid C.H., Greene T., et al. Factors other than glomerular filtration rate affect serum cystatin C levels // Kidney Int. 2009. Vol. 75, N. 6. P. 652–660. doi: 10.1038/ki.2008.638

[55] Liu X, Foster MC, Tighiouart H, et al. Non-GFR Determinants of low-molecular-weight serum protein filtration markers in CKD. Am J Kidney Dis. 2016;68(6):892–900. doi: 10.1053/j.ajkd.2016.07.021

[56] Liu X., Foster M.C., Tighiouart H., et al. Non-GFR determinants of low-molecular-weight serum protein filtration markers in CKD // Am J Kidney Dis. 2016. Vol. 68, N. 6. P. 892–900. doi: 10.1053/j.ajkd.2016.07.021

[57] Al Musaimi O, Abu-Nawwas AH, Al Shaer D, et al. Influence of age, gender, smoking, diabetes, thyroid and cardiac dysfunctions on cystatin C biomarker. Semergen. 2019;45(1):44–51. doi: 10.1016/j.semerg.2018.07.005

[58] Al Musaimi O., Abu-Nawwas A.H., Al Shaer D., et al. Influence of age, gender, smoking, diabetes, thyroid and cardiac dysfunctions on cystatin C biomarker // Semergen. 2019. Vol. 45, N. 1. P. 44–51. doi: 10.1016/j.semerg.2018.07.005

[59] Sazonova EG, Mokhort TV. Thyroid functioning in diabetes mellitus complicated with chronic renal disease. International journal of endocrinology. 2013;(2):62–67. EDN: QBCRIF

[60] Сазонова Е.Г., Мохорт Т.В. Тиреоидная функция при сахарном диабете, осложненном хронической болезнью почек // Международный эндокринологический журнал. 2013. №2(50). С. 62–67. EDN: QBCRIF

[61] Oberbauer R, Nenov V, Weidekamm C, et al. Reduction in mean glomerular pore size coincides with the development of large shunt pores in patients with diabetic nephropathy. Exp Nephrol. 2001;9(1):49–53. doi: 10.1159/000020698

[62] Oberbauer R., Nenov V., Weidekamm C., et al. Reduction in mean glomerular pore size coincides with the development of large shunt pores in patients with diabetic nephropathy // Exp Nephrol. 2001. Vol. 9, N. 1. P. 49–53. doi: 10.1159/000020698

[63] Pucci L, Triscornia S, Lucchesi D, et al. Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem. 2007;53(3):480–488. doi: 10.1373/clinchem.2006.076042

[64] Pucci L., Triscornia S., Lucchesi D., et al. Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients // Clin Chem. 2007. Vol. 53, N 3. P. 480–488. doi: 10.1373/clinchem.2006.076042

[65] Feng B, Lu Y, Ye L, et al. Mendelian randomization study supports the causal association between serum cystatin C and risk of diabetic nephropathy. Front Endocrinol. 2022;13. doi: 10.3389/fendo.2022.1043174

[66] Feng B., Lu Y., Ye L., et al. Mendelian randomization study supports the causal association between serum cystatin C and risk of diabetic nephropathy // Front Endocrinol. 2022. Vol. 13. doi: 10.3389/fendo.2022.1043174

[67] Liu J, Liu Z, Sun W, et al. Role of sex hormones in diabetic nephropathy. Front Endocrinol. 2023;14. doi: 10.3389/fendo.2023.1135530

[68] Liu J., Liu Z., Sun W., et al. Role of sex hormones in diabetic nephropathy // Front Endocrinol. 2023. Vol. 14. doi: 10.3389/fendo.2023.1135530

[69] Kitajima Y, Ono Y. Estrogens maintain skeletal muscle and satellite cell functions. J Endocrinol. 2016;229(3):267–275. doi: 10.1530/JOE-15-0476

[70] Kitajima Y., Ono Y. Estrogens maintain skeletal muscle and satellite cell functions // J Endocrinol. 2016. Vol. 229, N. 3. P. 267–275. doi: 10.1530/JOE-15-0476

[71] Arnal JF, Lenfant F, Metivier R, et al. Membrane and nuclear estrogen receptor alpha actions: from tissue specificity to medical implications. Physiol Rev. 2017;97(3):1045–1087. doi: 10.1152/physrev.00024.2016

[72] Arnal J.F., Lenfant F., Metivier R., et al. Membrane and nuclear estrogen receptor alpha actions: from tissue specificity to medical implications // Physiol Rev. 2017. Vol. 97, N. 3. P. 1045–1087. doi: 10.1152/physrev.00024.2016

[73] Wilkinson HN, Hardman MJ. The role of estrogen in cutaneous ageing and repair. Maturitas. 2017;103:60–64. doi: 10.1016/j.maturitas.2017.06.026

[74] Wilkinson H.N., Hardman M.J. The role of estrogen in cutaneous ageing and repair // Maturitas. 2017. Vol. 103. P. 60–64. doi: 10.1016/j.maturitas.2017.06.026

[75] Trenti A, Tedesco S, Boscaro C, et al. Estrogen, angiogenesis, immunity and cell metabolism: solving the puzzle. Int J Mol Sci. 2018;19(3):859. doi: 10.3390/ijms19030859

[76] Trenti A., Tedesco S., Boscaro C., et al. Estrogen, angiogenesis, immunity and cell metabolism: solving the puzzle // Int J Mol Sci. 2018. Vol. 19, N. 3. P. 859. doi: 10.3390/ijms19030859

[77] El-Gendy AA, Elsaed WM, Abdallah HI. Potential role of estradiol in ovariectomy-induced derangement of renal endocrine functions. Ren Fail. 2019;41(1):507–520. doi: 10.1080/0886022X.2019.1625787

[78] El-Gendy A.A., Elsaed W.M., Abdallah H.I. Potential role of estradiol in ovariectomy-induced derangement of renal endocrine functions // Ren Fail. 2019. Vol. 41, N. 1. P. 507–520. doi: 10.1080/0886022X.2019.1625787

[79] Vrtačnik P, Ostanek B, Mencej-Bedrač S, et al. The many faces of estrogen signaling. Biochem Med (Zagreb). 2014;24(3):329–342. doi: 10.11613/BM.2014.035

[80] Vrtačnik P., Ostanek B., Mencej-Bedrač S., et al. The many faces of estrogen signaling // Biochem Med (Zagreb). 2014. Vol. 24, N. 3. P. 329–342. doi: 10.11613/BM.2014.035

[81] Hara Y, Waters EM, McEwen BS, et al. Estrogen effects on cognitive and synaptic health over the lifecourse. Physiol Rev. 2015;95(3):785–807. doi: 10.1152/physrev.00036.2014

[82] Hara Y., Waters E.M., McEwen B.S., et al. Estrogen effects on cognitive and synaptic health over the lifecourse // Physiol Rev. 2015. Vol. 95, N. 3. P. 785–807. doi: 10.1152/physrev.00036.2014

[83] Arao Y, Korach KS. The physiological role of estrogen receptor functional domains. Essays Biochem. 2021;65(6):867–875. doi: 10.1042/EBC20200167

[84] Arao Y., Korach K.S. The physiological role of estrogen receptor functional domains // Essays Biochem. 2021. Vol. 65, N. 6. P. 867–875. doi: 10.1042/EBC20200167

[85] Ji H, Zheng W, Menini S, et al. Female protection in progressive renal disease is associated with estradiol attenuation of superoxide production. Gend Med. 2007;4(1):56–71. doi: 10.1016/s1550-8579(07)80009-x

[86] Ji H., Zheng W., Menini S., et al. Female protection in progressive renal disease is associated with estradiol attenuation of superoxide production // Gend Med. 2007. Vol. 4, N. 1. P. 56–71. doi: 10.1016/s1550-8579(07)80009-x

[87] Andreeva EN, Grigoryan OR. Endocrine gynecology: selected seminars. Dedov II, Mokrysheva NG, editors. Moscow: MEDpress-inform; 2023. (In Russ.)

[88] Андреева Е.Н., Григорян О.Р. Эндокринная гинекология: избранные семинары / под ред. Дедова И.И., Мокрышевой Н.Г. Москва: МЕДпресс-информ, 2023.

[89] Tolpygina MG. Ovulatory function of the ovaries in women with type 1 diabetes mellitus depending on compensation of carbohydrate metabolism [dissertation]. Saint Petersburg; 2019. Available from: https://ott.ru/files/news/pg/2019_tolpigina/dissertatsiia_tolpigina.pdf (In Russ.)

[90] Толпыгина М.Г. Овуляторная функция яичников у женщин с сахарным диабетом 1 типа в зависимости от компенсации углеводного обмена: автореф. дис. … канд. мед. наук. Санкт Петербург, 2019. Режим доступа: https://ott.ru/files/news/pg/2019_tolpigina/dissertatsiia_tolpigina.pdf. Дата обращения: 28.10.2023.

[91] Whitworth KW, Baird DD, Stene LC, et al. Fecundability among women with type 1 and type 2 diabetes in the Norwegian Mother and Child Cohort Study. Diabetologia. 2011;54(3):516–522. doi: 10.1007/s00125-010-2003-6

[92] Whitworth K.W., Baird D.D., Stene L.C., et al. Fecundability among women with type 1 and type 2 diabetes in the Norwegian Mother and Child Cohort Study // Diabetologia. 2011. Vol. 54, N. 3. P. 516–522. doi: 10.1007/s00125-010-2003-6

[93] All-Russian public organization RAHR. National register of ART. Report for 2021. Saint Petersburg; 2023. Available from: https://www.rahr.ru/d_registr_otchet/RegistrVRT_2021.pdf (In Russ.)

[94] Общероссийская общественная организация РАРЧ. Национальный регистр ВРТ. Отчет за 2021. Санкт-Петербург, 2023. Режим доступа: https://www.rahr.ru/d_registr_otchet/RegistrVRT_2021.pdf. Дата обращения: 28.10.2023.

[95] Smeenk J, Wyns C, De Geyter Ch, et al. Assisted Reproductive Technology (ART) in Europe 2020 and development of a strategy of vigilance: Preliminary results generated from European registers by the ESHRE EIM Consortium. Hum Reprod. 2023;38(suppl 1). doi: 10.1093/humrep/dead093.186

[96] Smeenk J., Wyns C., De Geyter Ch., et al. Assisted Reproductive Technology (ART) in Europe 2020 and development of a strategy of vigilance: preliminary results generated from European registers by the ESHRE EIM Consortium // Hum Reprod. 2023. Vol. 38, Suppl. 1. doi: 10.1093/humrep/dead093.186

[97] Adamson GD, Dyer S, Zegers-Hochschild F, et al. ICMART preliminary world report 2019. Hum Reprod. 2023;38(suppl 1). doi: 10.1093/humrep/dead093.187

[98] Adamson G.D., Dyer S., Zegers-Hochschild F., et al. ICMART preliminary world report 2019 // Hum Reprod. 2023. Vol. 38, Suppl. 1. doi: 10.1093/humrep/dead093.187

[99] Larsen MD, Jensen DM, Fedder J, et al. Live-born children after assisted reproduction in women with type 1 diabetes and type 2 diabetes: a nationwide cohort study. Diabetologia. 2020;63(9):1736–1744. doi: 10.1007/s00125-020-05193-6

[100] Larsen M.D., Jensen D.M., Fedder J., et al. Live-born children after assisted reproduction in women with type 1 diabetes and type 2 diabetes: a nationwide cohort study // Diabetologia. 2020. Vol. 63, N. 9. P. 1736–1744. doi: 10.1007/s00125-020-05193-6

[101] Misharina EV, Yarmolinskaya MI, Borovik NV. Algorithms of preparation for art programs in patients with type 1 diabetes mellitus. Obstetrics and Gynegology. 2022;9(suppl):50–56.

[102] Мишарина Е.В., Ярмолинская М.И., Боровик Н.В. Алгоритмы подготовки к программам вспомогательных репродуктивных технологий у пациенток с сахарным диабетом 1 типа // Акушерство и Гинекология. 2022. № S9. С. 50–56.

[103] Relph S, Patel T, Delaney L, et al. Adverse pregnancy outcomes in women with diabetes-related microvascular disease and risks of disease progression in pregnancy: a systematic review and meta-analysis. PLoS Med. 2021;18(11). doi: 10.1371/journal.pmed.1003856

[104] Relph S., Patel T., Delaney L., et al. Adverse pregnancy outcomes in women with diabetes-related microvascular disease and risks of disease progression in pregnancy: a systematic review and meta-analysis // PLoS Med. 2021. Vol. 18, N. 11. doi: 10.1371/journal.pmed.1003856

[105] Bogdanova MA, Vartanova IV, Gzgzyan AM, et al. In vitro fertilization: a practical guide for doctors. Kogan IYu, editor. Moscow: GEOTAR-Media; 2021. (In Russ.)

[106] Богданова М.А., Вартанова И.В., Гзгзян А.М., и др. Экстракорпоральное оплодотворение: практическое руководство для врачей / под ред. Когана И.Ю. Москва: ГЭОТАР-Медиа, 2021.

[107] Grigoryan OR, Andreeva EN. Ispol’zovanie mikronizirovannogo natural’nogo progesterona v terapii narusheniy menstrual’nogo tsikla u devushek s sakharnym diabetom 1 tipa v sochetanii s gipertriglitseridemiey. Diabetes mellitus. 2008;11(2):51–54. EDN: KXEGZL doi: 10.14341/2072-0351-5760

[108] Григорян О.Р., Андреева Е.Н. Использование микронизированного натурального прогестерона в терапии нарушений менструального цикла у девушек с сахарным диабетом 1-го типа в сочетании с гипертриглицеридемией // Сахарный диабет. 2008. Т. 11, № 2. С. 51–54. EDN: KXEGZL doi: 10.14341/2072-0351-5760

[109] Misharina EV, Tiselko AV, Yarmolinskaya MI, et al. In vitro fertilization as a method of infertility treatment in women with type 1 diabetes mellitus. Diabetes mellitus. 2018;21(5):425–430. EDN: YPVIOT doi: 10.14341/DM9573

[110] Мишарина Е.В., Тиселько А.В., Ярмолинская М.И., и др. Экстракорпоральное оплодотворение как метод лечения бесплодия у женщин с сахарным диабетом 1 типа // Сахарныйдиабет. 2018. Т. 21, № 5. С. 425–430. EDN: YPVIOT doi: 10.14341/DM9573

[111] Shilova ES, Borovik NV, Yarmolinskaya MI. Diabetic nephropathy in type 1 diabetes and pregnancy. Modern view of the problem. Diabetes mellitus. 2020;23(4):340–348. EDN: ITLLHE doi: 10.14341/DM12228

[112] Шилова Е.С., Боровик Н.В., Ярмолинская М.И. Диабетическая нефропатия у беременных с сахарным диабетом 1 типа, современный взгляд на проблему // Сахарный диабет. 2020. Т. 23, № 4. С. 340–348. EDN: ITLLHE doi: 10.14341/DM12228

[113] Dedov II, Shestakova MV, Mayorov AYu, et al. “Standards of specialized diabetes care” edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 10th edition. Diabetes mellitus. 2021;24(1S):1–148. doi: 10.14341/DM12802

[114] Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. «Алгоритмы специализированной медицинской помощи больным сахарным диабетом» под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 10-й выпуск // Сахарный диабет. 2021. Т. 24, № S1. С. 1–148. doi: 10.14341/DM12802

[115] National Collaborating Centre for Women’s and Children’s Health (UK). Diabetes in Pregnancy: Management of Diabetes and Its Complications from Preconception to the Postnatal Period. NICE guideline. London: National Institute for Health and Care Excellence (UK); 2015. Available from: https://diabetesneeds.co.uk/wp-content/uploads/2024/01/NICE-DIP-guideline-2.pdf

[116] National Collaborating Centre for Women’s and Children’s Health (UK). Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period. NICE guideline. London: National Institute for Health and Care Excellence (UK); 2015. Режим доступа: https://diabetesneeds.co.uk/wp-content/uploads/2024/01/NICE-DIP-guideline-2.pdf. Дата обращения: 19.01.2024

[117] Piccoli GB, Zakharova E, Attini R, et al. Pregnancy in chronic kidney disease: need for higher awareness. a pragmatic review focused on what could be improved in the different CKD stages and phases. J Clin Med. 2018;7(11):415. doi: 10.3390/jcm7110415

[118] Piccoli G.B., Zakharova E., Attini R., et al. Pregnancy in chronic kidney disease: need for higher awareness. a pragmatic review focused on what could be improved in the different CKD stages and phases // J Clin Med. 2018. Vol. 7, N. 11. P. 415. doi: 10.3390/jcm7110415

[119] Piccoli GB, Clari R, Ghiotto S, et al. Type 1 diabetes, diabetic nephropathy, and pregnancy: a systematic review and meta-study. Rev Diabet Stud. 2013;10(1):6–26. doi: 10.1900/RDS.2013.10.6

[120] Piccoli G.B., Clari R., Ghiotto S., et al. Type 1 diabetes, diabetic nephropathy, and pregnancy: a systematic review and meta-study // Rev Diabet Stud. 2013. Vol. 10, N. 1. P. 6–26. doi: 10.1900/RDS.2013.10.6

[121] Piccoli GB, Minelli F, Versino E, et al. Pregnancy in dialysis patients in the new millennium: a systematic review and meta-regression analysis correlating dialysis schedules and pregnancy outcomes. Nephrol Dial Transplant. 2016;31(11):1915–1934. doi: 10.1093/ndt/gfv395

[122] Piccoli G.B., Minelli F., Versino E., et al. Pregnancy in dialysis patients in the new millennium: a systematic review and meta-regression analysis correlating dialysis schedules and pregnancy outcomes // Nephrol Dial Transplant. 2016. Vol. 31, N. 11. P. 1915–1934. doi: 10.1093/ndt/gfv395

[123] Webster P, Lightstone L, McKay DB, et al. Pregnancy in chronic kidney disease and kidney transplantation. Kidney Int. 2017;91(5):1047–1056. doi: 10.1016/j.kint.2016.10.045

[124] Webster P., Lightstone L., McKay D.B., et al. Pregnancy in chronic kidney disease and kidney transplantation // Kidney Int. 2017. Vol. 91, N. 5. P. 1047–1056. doi: 10.1016/j.kint.2016.10.045

RIGHTS & PERMISSIONS

Eсо-Vector